These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparison of localized versus systemic levels of Matrix metalloproteinases (MMPs), its tissue inhibitors (TIMPs) and cytokines in tuberculous and non-tuberculous pleuritis patients. Sundararajan S; Babu S; Das SD Hum Immunol; 2012 Oct; 73(10):985-91. PubMed ID: 22820625 [TBL] [Abstract][Full Text] [Related]
8. Strongyloides stercoralis Coinfection Is Associated With Greater Disease Severity, Higher Bacterial Burden, and Elevated Plasma Matrix Metalloproteinases in Pulmonary Tuberculosis. Kumar NP; Kathamuthu GR; Moideen K; Banurekha VV; Nair D; Fay MP; Nutman TB; Babu S J Infect Dis; 2020 Aug; 222(6):1021-1026. PubMed ID: 32307511 [TBL] [Abstract][Full Text] [Related]
9. Altered circulating levels of matrix metalloproteinases and inhibitors associated with elevated type 2 cytokines in lymphatic filarial disease. Anuradha R; George JP; Pavankumar N; Kumaraswami V; Nutman TB; Babu S PLoS Negl Trop Dis; 2012; 6(6):e1681. PubMed ID: 22679524 [TBL] [Abstract][Full Text] [Related]
10. Effects of choline treatment in concentrations of serum matrix metalloproteinases (MMPs), MMP tissue inhibitors (TIMPs) and immunoglobulins in an experimental model of canine sepsis. Kocaturk M; Eralp-Inan O; Tvarijonaviciute A; Cansev M; Ozyigit MO; Ceron JJ; Yilmaz Z; Kahraman MM Vet Immunol Immunopathol; 2016 Nov; 180():9-14. PubMed ID: 27692098 [TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283 [TBL] [Abstract][Full Text] [Related]
12. Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor. Tency I; Verstraelen H; Kroes I; Holtappels G; Verhasselt B; Vaneechoutte M; Verhelst R; Temmerman M PLoS One; 2012; 7(11):e49042. PubMed ID: 23145060 [TBL] [Abstract][Full Text] [Related]
13. Dynamic changes of matrix metalloproteinases and their tissue inhibitors in severe sepsis. Mühl D; Nagy B; Woth G; Falusi B; Bogár L; Weber G; Lantos J J Crit Care; 2011 Dec; 26(6):550-5. PubMed ID: 21530151 [TBL] [Abstract][Full Text] [Related]
14. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. Lorenzl S; Buerger K; Hampel H; Beal MF Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439 [TBL] [Abstract][Full Text] [Related]
15. The effect of gender and genetic polymorphisms on matrix metalloprotease (MMP) and tissue inhibitor (TIMP) plasma levels in different infectious and non-infectious conditions. Collazos J; Asensi V; Martin G; Montes AH; Suárez-Zarracina T; Valle-Garay E Clin Exp Immunol; 2015 Nov; 182(2):213-9. PubMed ID: 26206176 [TBL] [Abstract][Full Text] [Related]
16. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. Tanaka K; Essick EE; Doros G; Tanriverdi K; Connors LH; Seldin DC; Sam F J Am Heart Assoc; 2013 Mar; 2(2):e005868. PubMed ID: 23537813 [TBL] [Abstract][Full Text] [Related]
17. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. Todd JL; Vinisko R; Liu Y; Neely ML; Overton R; Flaherty KR; Noth I; Newby LK; Lasky JA; Olman MA; Hesslinger C; Leonard TB; Palmer SM; Belperio JA; BMC Pulm Med; 2020 Mar; 20(1):64. PubMed ID: 32171287 [TBL] [Abstract][Full Text] [Related]
19. Metalloproteinases and their inhibitors are associated with pulmonary arterial stiffness and ventricular function in pediatric pulmonary hypertension. Schäfer M; Ivy DD; Nguyen K; Boncella K; Frank BS; Morgan GJ; Miller-Reed K; Truong U; Colvin K; Yeager ME Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H242-H252. PubMed ID: 34085841 [TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, aminoterminal propeptide of procollagen type III, and hyaluronan in sera and tissue of patients with capsular contracture after augmentation with Trilucent breast implants. Ulrich D; Lichtenegger F; Eblenkamp M; Repper D; Pallua N Plast Reconstr Surg; 2004 Jul; 114(1):229-36. PubMed ID: 15220598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]